Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer

Virology

Volumn 249, Issue 1, 1998, Pages 89-97

  Restifo, Nicholas P ^a   Surman, Deborah R ^a   Zheng, Hongyong ^b   Palese, Peter ^b   Rosenberg, Steven A ^a   García Sastre, Adolfo ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; EPITOPE; RECOMBINANT VACCINE; SIGNAL PEPTIDE; TUMOR VACCINE; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC TRANSFECTION; IMMUNOGENICITY; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; TUMOR REGRESSION; VACCINATION;

ANIMALIA; INFLUENZA A VIRUS; INFLUENZA VIRUS; MURINAE; RNA VIRUSES;

EID: 0032530630     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9330     Document Type: Article

References (39)

1. Andino R., Silvera D., Suggett S. D., Achacoso P. L., Miller C. J., Baltimore D., Feinberg M. B. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science. 265:1994;1448-1451.
2. Ansardi D. C., Moldoveanu Z., Porter D. C., Walker D. E., Conry R. M., LoBuglio A. F., McPherson S., Morrow C. D. Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res. 54:1994;6359-6364.
3. Bronte V., Carroll M. W., Goletz T. J., Wang M., Overwijk W. W., Marincola F., Rosenberg S. A., Moss B., Restifo N. P. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA. 94:1997;3183-3188.
4. Bronte V., Tsung K., Rao J. B., Chen P. W., Wang M., Rosenberg S. A., Restifo N. P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:1995;5282-5292.
5. Carroll M. W., Overwijk W., Chamberlain R. S., Rosenberg S. A., Moss B., Restifo N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model. Vaccine. 15:1997;387-394.
6. Chanock R. M., Murphy B. R. Use of temperature-sensitive and cold-adapted mutant viruses in immunoprophylaxis of acute respiratory tract disease. Rev. Infect. Dis. 2:1980;421-432.
7. Chen P. W., Wang M., Bronte V., Zhai Y., Rosenberg S. A., Restifo N. P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:1996;224-231.
8. Crowe J. E. Jr., Bui P. T., Siber G. R., Elkins W. R., Chanock R. M., Murphy B. R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine. 13:1995;847-855.
9. García-Sastre A., Muster T., Barclay W. S., Percy N., Palese P. Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus. J. Virol. 68:1994;6254-6261.
10. García-Sastre A., Palese P. Genetic manipulation of negative-strand RNA virus genomes. Annu. Rev. Microbiol. 47:1993;765-790.
11. Gavin M. A., Gilbert M. J., Riddell S. R., Greenberg P. D., Bevan M. J. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol. 151:1993;3971-3980.
12. Greenberg P. D. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:1991;281-355.
13. Irvine K. R., McCabe B. J., Rosenberg S. A., Restifo N. P. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 154:1995;4651-4657.
14. Irvine K. R., Rao J. B., Rosenberg S. A., Restifo N. P. Cytokin enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156:1996;238-245.
15. Irvine K. R., Chamberlain R. S., Shulman E. P., Surman D. R., Rosenberg S. A., Restifo N. P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89:1997;1595-1601.
16. Kawakami Y., Rosenberg S. A. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 14:1997;173-192.
17. Kawakita M., Rao G. S., Ritchey J. K., Ornstein D. K., Hudson M. A., Tartaglia J., Paoletti E., Humphrey P. A., Harmon T. J., Ratliff T. L. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth [see comments]. J. Natl. Cancer Inst. 89:1997;428-436.
18. Kim C. J., Prevette T., Cormier J., Overwijk W., Roden M., Restifo N. P., Rosenberg S. A., Marincola F. M. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother. 20:1997;276-286.
19. Lamb R. A., Krug R. M. Fields Virology. 1996;Lippincott Raven, Philadelphia. p. 1353-1396.
20. Maassab, H. F. LaMontagne, J. R. DeBorde, D. C. 1988, In, Vaccines, S. A. PlotkinE. A. Mortimer, 435, 457, Saunders, Philadelphia.
21. McCabe B. J., Irvine K. R., Nishimura M. I., Yang J. C., Spiess P. J., Shulman E. P., Rosenberg S. A., Restifo N. P. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 55:1995;1741-1747.
22. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA. 93:1996;11341-11348.
23. Murata K., García-Sastre A., Tsuji M., Rodrigues M., Rodriguez D., Rodriguez J. R., Nussenzweig R. S., Palese P., Esteban M., Zavala F. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol. 173:1996;96-107.
24. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., Grassauer A., Engelhardt O. G., García-Sastre A., Palese P., Katinger H. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69:1995;6678-6686.
25. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:1994;4031-4034.
26. Muster T., Subbarao E. K., Enami M., Parvin J., Palese P. An influenza A virus containing influenza B virus 5′ and 3′ noncoding regions of the neuraminidase gene is attenuated in mice. Proc. Natl. Acad. Sci. USA. 88:1991;5177-5181.
27. Palese P., Zheng H., Engelhardt O. G., Pleschka S., García-Sastre A. Negative-strand RNA viruses: Genetic engineering and applications. Proc. Natl. Acad. Sci. USA. 93:1996;11354-11358.
28. Randrianarison-Jewtoukoff V., Perricaudet M. Recombinant adenoviruses as vaccines. Biologicals. 23:1995;145-157.
29. Rao J. B., Chamberlain R. S., Bronte V., Carroll M. W., Irvine K. R., Moss B., Rosenberg S. A., Restifo N. P. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. J. Immunol. 156:1996;3357-3365.
30. Restifo N. P. The new vaccines: Building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8:1996;658-663.
31. Restifo N. P., Bacik I., Irvine K. R., Yewdell J. W., McCabe B. J., Anderson R. W., Eisenlohr L. C., Rosenberg S. A., Bennink J. R. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:1995;4414-4422.
32. Restifo N. P., Esquivel F., Kawakami Y., Yewdell J. W., Mule J. J., Rosenberg S. A., Bennink J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:1993;265-272.
33. Rodrigues M., Li S., Murata K., Rodriguez D., Rodriguez J. R., Bacik I., Bennink J. R., Yewdell J. W., García-Sastre A., Nussenzweig R. S., Esteban M., Palese P., Zavala F. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153:1994;4636-4648.
34. Rosenberg S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:1997;175-182.
35. Rosenberg S. A., White D. E. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:1996;81-84.
36. Snyder M. H., London W. T., Maassab H. F., Chanock R. M., Murphy B. R. A 36 nucleotide deletion mutation in the coding region of the NS1 gene of an influenza A virus RNA segment 8 specifies a temperature-dependent host range phenotype. Virus Res. 15:1990;69-83.
37. Steinman R. M. Dendritic cells and immune-based therapies. Exp. Hematol. 24:1996;859-862.
38. Wang M., Bronte V., Chen P. W., Gritz L., Panicali D., Rosenberg S. A., Restifo N. P. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:1995;4685-4692.
39. Yee C., Gilbert M. J., Riddell S. R., Brichard V. G., Fefer A., Thompson J. A., Boon T., Greenberg P. D. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. 157:1996;4079-4086.